Gabapentin in Fibromyalgia Trial (GIFT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00057278|
Recruitment Status : Completed
First Posted : March 31, 2003
Last Update Posted : December 19, 2007
|Condition or disease||Intervention/treatment||Phase|
|Fibromyalgia||Drug: gabapentin||Phase 2 Phase 3|
Fibromyalgia, a chronic musculoskeletal pain disorder of unknown etiology, is characterized by widespread musculoskeletal pain, fatigue, and multiple tender points; the disease affects 3 to 6 million Americans. A person is considered to have fibromyalgia if he or she has widespread pain in combination with tenderness in at least 11 of 18 specific tender point sites.
Treatment of fibromyalgia requires a comprehensive approach and includes aerobic exercise, heat and massage, antidepressant medications, and relaxation. Gabapentin, a medication used to treat seizures, has been shown to work on pain transmission pathways and may relieve the pain associated with fibromyalgia. This study will assess the efficacy of gabapentin in reducing pain severity in fibromyalgia as measured by the average pain item of the Brief Pain Inventory (BPI) score.
Patients will be randomized to receive gabapentin or placebo. The gabapentin dose will be titrated for persisting symptoms and as tolerated during the first 6 weeks of the study, reaching final doses between 1800 mg/day and 2400 mg/day. Patients will then continue on the final dose for the remaining 6 weeks of the study. Following completion of the 12 week treatment phase, patients will be tapered off of the medication over 1 week.
The effectiveness of gabapentin will be assessed using the BPI. The BPI is a self-administered questionnaire that measures the severity of pain and the interference of pain on function over the past 24 hours. Other assessments will include the total Fibromyalgia Impact Questionnaire (FIQ) score; six 11-point Likert-type scales in the FIQ that measure pain, fatigue, morning tiredness, stiffness, anxiety, and depression; the mean tender point pain threshold; Clinical Global Impression of Severity (CGI-Severity); Patient Global Impression of Improvement (PGI-Improvement); the Short-form McGill Pain Questionnaire (SF-MPQ); the Medical Outcomes Study Short Form-36 (SF-36); the Montgomery Asberg Depression Rating Scale (MADRS); and the Medical Outcomes Sleep Scale (MOS-Sleep).
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Gabapentin in Fibromyalgia Trial (GIFT)|
|Study Start Date :||March 2003|
|Actual Study Completion Date :||January 2006|
- Brief Pain Inventory (BPI) average pain item
- Fibromyalgia Impact Questionnaire
- Mean Tender Point Pain Threshold
- McGill Pain Questionnaire
- Clinical Global Impression of Severity
- Patient Global Impression of Improvement
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Medical Outcomes Study Short Form-36 (SF-36)
- Medical Outcomes Sleep Scale (MOS-Sleep)
- Fibromyalgia Rating Scale (FRS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00057278
|United States, Massachusetts|
|McLean Hospital/Harvard Medical School (must live in the Boston, MA area)|
|Belmont, Massachusetts, United States, 02478|
|Newton-Wellesley Hospital (must live in the Boston, MA area)|
|Newton, Massachusetts, United States, 02462|
|United States, Ohio|
|University of Cincinnati College of Medicine, Department of Psychiatry (must live in the Cincinnati, OH area)|
|Cincinnati, Ohio, United States, 45219|
|Principal Investigator:||Lesley M. Arnold, MD||University of Cincinnati|